Purpose: As a progressive condition, glaucoma may impair health-related quality of life (HRQoL), due to vision loss and other factors. This study evaluated HRQoL in a cohort of patients treated for primary open-angle glaucoma (POAG) and assessed its association with clinical features. Methods: This was an Italian, multicentre, cross-sectional, observational study with the subgroup of newly diagnosed patients with POAG prospectively followed up for one year. Patients with previous or new diagnosis (or strong clinical suspicion) of POAG aged >18 years were considered eligible. Information was collected on demographic characteristics, medical history, clinical presentation and POAG treatments. HRQoL was measured using the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) and Glaucoma Symptom Scale (GSS). Subscale and total scores were obtained and a Pearson correlation coefficient between instruments' scores calculated. Results: A total of 3227 patients were enrolled from 2012 to 2013 and 3169 were analysed. Mean age was 66.9 years. A total of 93.8% had a previous diagnosis (median duration: 8.0 years). Median values for mean deviation and pattern standard deviation were 3.9 and 3.6 dB, respectively. Mean scores on most subscales of the NEI-VFQ-25 exceeded 75.0 and mean GSS subscale scores ranged between 70.8 and 79.7 (with a total mean score of 74.8). HRQoL scores on both scales were significantly inversely associated with POAG severity. Conclusion: In this large sample of Italians treated for POAG, disease severity was limited and HRQoL scores were high. QoL decreased with advancing disease severity. These findings confirm the role of vision loss in impairing QoL in POAG, underlying the importance of timely detection and appropriate treatment.
Introduction
Glaucoma is a leading cause of irreversible visual loss worldwide (Giangiacomo 2009 ). Data from population-based surveys indicate that 1.86% of adults ≥40 years old has glaucoma, which equates to 60 million people worldwide being affected and 8.4 million being bilaterally blind (Giangiacomo 2009; Quigley 2011) . Of several types of glaucoma, primary open-angle glaucoma (POAG) is the most common. Populations of European ancestry are particularly affected (Giangiacomo 2009; Kwon et al. 2009 ). In Italy, a population-based survey reported a POAG prevalence of 1.4% in a population of 5000 adults of rural northern Italy (Bonomi et al. 1998) .
As a chronic and progressive condition, POAG can significantly affect quality of life (QoL). Visual impairment, associated with limitation of daily function and loss of autonomy, may lead to or exacerbate depression, loneliness and anxiety (Dodds 1991; Hinds et al. 2003) , especially in the elderly (Baker & Winyard 1998) .
However, other non-visual factors, such as distress caused by the knowledge of having a blinding illness, cost of treatment or problems and adverse reactions to glaucoma therapies, have also been frequently implicated as factors negatively impacting QoL in these patients (Stuck et al. 1999; Odberg et al. 2001a; Spaeth et al. 2006) .
Health-related QoL (HRQoL) measures can be indicative of the diseaserelated burden experienced by the patient, and its importance is increasingly recognized. In fact, the very aim of glaucoma management is the patient's autonomy and preservation of QoL at a sustainable cost (European Glaucoma Society 2014) .
Compared to the state of evidence on the impact of other chronic diseases on QoL, the existing literature on glaucoma-related QoL is limited (Mills et al. 2009 ). Moreover, the relative role of different factors in affecting QoL in patients with POAG merits investigation and requires a sufficiently numerous patient population.
The investigators of the Italian Study Group on QoL in Glaucoma have designed a study with both a cross-sectional and a prospective part. The aim of the cross-sectional part was the evaluation of HRQoL in a large cohort of patients with POAG, and the assessment of the contribution of socio-demographic and clinical features. Vice versa, the prospective part aimed to assess the changes in QoL measures over 12-month follow-up. This first report describes the study design, sample characteristics and overall results on QoL of the cross-sectional cohort study.
Methods
This was an Italian, multicentre observational study. In an effort to capture a cohort representative of the population of Italian patients with POAG, the ophthalmic centres invited to participate comprised of both academic and non-academic institutions with a nationwide geographical distribution.
The study was conducted in accordance with the tenets of the Declaration of Helsinki and the Guidelines for Good Clinical Practice. The institutional review board of each participating centre approved the protocol. The participants gave informed consent after the nature and purpose of the survey were fully explained. Data were handled according to current Italian legislation on observational studies.
Patients and procedures
Patients with a previous or new diagnosis (or strong clinical suspicion) of (Topouzis et al. 2008) .
Eligible patients underwent a comprehensive ocular examination and treatment was started or continued, as clinically indicated. Demographic characteristics, medical and ophthalmic history, and information on surgical and medical treatments of POAG were collected and QoL questionnaires administered. Glaucoma severity was classified in all patients according to Glaucoma Staging System 2 (Brusini & Filacorda 2006) . Only reliable visual field data (i.e. visual fields were considered reliable if false-positive responses were fewer than 15% and a clear blind spot could be seen in the visual field printouts, threshold value <10 decibel [dB]) were included in the analysis.
Study instruments
Study HRQoL instruments comprised of the validated Italian versions of the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) (Rossi et al. 2003 ) and the Glaucoma Symptom Scale (GSS) questionnaire (Rossi et al. 2013) .
GSS (Lee et al. 1998 ), a glaucomaspecific instrument, includes 10 items grouped into two domains (Symp-6 for non-visual symptoms and Func-4 for visual symptoms). Each eye is assessed separately for the presence of ten specific symptoms, using a 0-100 scale, where zero represents the highest grade of disturbance and 100 indicates the symptom's absence. The subscale score is the unweighted average of subscale score of each eye. Similarly, the total GSS score is the mean of the 10 subscale scores. Hence, GSS scores can be calculated as average between the two eyes or for each eye separately.
NEI-VFQ-25 is a self-administered, 25-item, 12-subscale questionnaire designed to measure vision-dependent function and used to assess impact of different of ocular conditions on HRQoL (Mangione et al. 2001) . Each subscale receives a score of 0-100, where higher scores reflect better vision-related QoL. The global score is the mean of the 11 subscale scores, excluding the general health item.
Statistical consideration
In Italy, there are currently approximately 500 000 patients with POAG managed in 50 specialized glaucoma centres (Cedrone et al. 2008) . Based on this assumption, a cohort of at least 3000 patients enrolled by approximately 20 ophthalmic centres was considered representative of the Italian population of patients with POAG.
Descriptive summary statistics are presented as mean, standard deviation, minimum and maximum values, and/or median, 25th and 75th percentiles (Q1, Q3), for continuous variables. Absolute frequency and percentage were used for categorical variables. The Spearman rank correlation test was used to study the strength of correlation between each single subscale and the mean total scores of the two study instruments. Correlation coefficients >0.5 were considered large, 0.5-0.3 moderate, 0.3-0.1 small and smaller than 0.1 insubstantial (Cohen 1988) .
For all analyses, we have considered patients as unit of analysis; for GSS Questionnaire, the mean of the two eyes was used.
The association between QoL subscales and the severity of glaucoma, as expressed by the Glaucoma Staging System 2, was analysed by means of linear regression models.
All analyses were performed with the SAS software version 9.1.3 (SAS Institute Inc, NC, USA).
Results
Twenty academic and non-academic ophthalmic centres participated in this study. Table 1 illustrates the geographical distribution of the centres and the accrual by Italian region. From March 2012 until July 2013, 3227 patients were enrolled in these centres. The information provided by fifty-eight patients (1.8%) was incomplete. Therefore, the statistical analysis was performed on data from 3169 study participants. Tables 2 and 3 summarize the sociodemographic and clinical characteristics of the participants. A total of 49.8% of participants were females, and mean age was 66.9 years (SD 12.1). A total of 93.8% patients had a previous diagnosis of POAG with median duration of 8.0 years. Median values (Q1, Q3) for mean deviation (MD), pattern standard deviation (PSD) and visual field index (VFI) were À3.90 dB (À8.50, À1.55), 3.60 dB (2.01, 6.65) and 93.0 (80.5, 97.5), respectively. Severity assessment, available for 3122 patients, showed mild disease (Stage ≤1) in 31.4% patients and advanced disease (stage ≥4) in 32.2%. For patients with stage 4 disease, the range of MD values was À15 to À21 dB and the range of PSD values was 14 to 20 dB. For patients with stage 5 disease, the MD values were <À21 dB and the PSD values >20 dB.
A total of 97.5% of patients had received previous medical and/or surgical treatment for glaucoma. Previous and concomitant treatments are presented in Table 4 .
Overall, 41.2% patients reported at least one risk factor for glaucoma, the most common being positive family history (35.6%). The most frequent self-reported comorbidities included systemic hypertension (53.2%) and hyperlipidaemia (26.2%). Risk factors for glaucoma and systemic conditions are shown in Fig. 1 . Table 5 depicts the subscale and total scores of the NEI-VFQ-25 questionnaire. The mean total score was 83.6 (SD 15.1). Particularly high scores were reported in the domains of social functioning (94.1) and dependency (92.0), while the domains 'general health' and 'general vision' yielded relatively lower scores (56.7 and 60.4, respectively). Table 6 shows the subscale and total scores for GSS. The total mean score was 74.9 (SD 19.8). The mean score of the visual symptoms domain (Func-4) was 75.9 and that of the non-visual symptoms domain Symp-6 was 74.9. Most scales of both questionnaires showed a ceiling effect (i.e. clustering of scores at the upper level), with a consequent reduction in their discrimination power.
HRQoL scores

HRQoL and glaucoma severity
A clear and highly significant association (p < 0.001) has been observed between most subscale and total scores and the severity of glaucoma, as expressed by the Glaucoma Staging System 2 (Figs 2 and 3) , with the exception of the GSS Symp-6 score for nonvisual disturbances (p = 0.1396). The NEI-VFQ-25 total mean score was reduced from 92.7 in patients with glaucoma stage 0-74.3 in patients with stage 5 disease. The worst affected domains were 'general vision' (69.2 in stage 0-51.3 in stage 5), near activities (94.4-71.0) and driving (93.6-68.3). Table 7 summarizes the results of the correlation analysis. Overall, specific GSS subscales showed correlation with NEI-VFQ-25 subscales designed to capture similar constructs, but did not correlate with subscales describing different HRQOL domains. The Symp-6 score highly correlated with the NEI-VFQ-25 pain subscale (r = 0.624), which assesses the impact of ocular pain or discomfort. Func-4 score showed a large correlation with the distant activities subscale (r = 0.533).
Correlation between HRQoL instruments
Discussion
The issue of QoL in patients with glaucoma has gained considerable interest in recent years (Glen et al. 2011 ), but the amount and quality of information remain incomplete (Mills et al. 2009 ). This is partially due to the fact that the objective indicators currently employed to describe glaucoma-related visual damage, such as visual fields, may fail to fully capture the negative impact of the disease and its treatment on patient perception of well-being (Odberg et al. 2001b) . In fact, the assessment of the degree of glaucomatous visual field loss that can cause significant deterioration in a patient's ability to function independently (Varma et al. 2010 ) is not straightforward. Moreover, HRQoL in glaucoma may be influenced by multiple factors more generally related to the burden of the disease and its treatments.
A better understanding of patients' HRQoL can help clinicians in customizing disease management and tailoring treatment and promote guidelines regarding patients' preferences, daily routine and safety (Glen et al. 2011) . We assessed HRQoL and visionrelated QoL in a large sample of patients treated for glaucoma using the NEI-VFQ-25 and GSS instruments. Twenty-one of the 50 clinical centres caring for the currently diagnosed 500 000 patients with POAG participated in this study, enrolling 3229 patients. Although the number of patients from each geographical location is imbalanced, it does reflect the different population density and medical centre density throughout the country.
Three different types of QoL questionnaires can be used in a research setting similar to ours, including general health-related QoL, vision-related QoL and specific glaucoma-related QoL. In our study, we opted for two QoL questionnaires: the NEI-VFQ-25 that evaluates the impact of visual disorders on a wide range of functional and self-perceived QoL domains, and the glaucoma-specific GSS that scores the gravity of the visual and non-visual signs and symptoms of this disease. Both instruments are self-administered and have been fully validated in Italian (Rossi et al. 2003 (Rossi et al. , 2013 . The analysed patient sample had mild/moderate glaucoma (median mean deviation: À3.90 dB, median visual field index: 93%); only about a third of the participants (32.2%) had advanced glaucoma (stage 4 or 5).
Questionnaire acceptability among survey participants was excellent both for GSS and for NEI-VFQ-25. The percentage of missing item-level responses was always below 1.7%, with the exception of the driving subscale of NEI-VFQ-25, presumably due to the large proportion of non-drivers among study participants.
Overall, HRQoL appeared to be well maintained in our population with mean scores >70 in most dimensions, except for general vision and general health. This finding reflects the fact that most of our participants had mild glaucoma and confirms previous findings that vision-related QoL remains relatively intact as long as visual fields are not severely affected (McKeanCowdin et al. 2008; Labiris et al. 2010; Onakoya et al. 2012; Wolfram et al. 2013) .
Vice versa, the lower scores on general health and vision dimensions may be due to the advanced age of the studied population (mean: 66.9, SD: 12.1 years) or due to the fact that glaucomatous damage per se can be associated with a reduction in general health-related QoL. W€ andell et al. (1997) used the generic QoL instrument-Swedish Health-Related Quality of Life Survey and observed that, compared to controls, glaucoma patients with moderate calculated binocular visual field defects had significantly lower scores in 2 of 13 general health and functioning subscales.
Notwithstanding the good overall results, HRQoL mean total scores, as well as scores on most subscales of both instruments, showed a significant inverse association with disease severity expressed by the Glaucoma staging system. van Gestel et al. (2010) showed a similar trend in their cross-sectional study of 537 ocular hypertension and POAG patients. Their study found a relationship between MD and HRQoL that was independent of patient demographics, visual acuity, medication adverse events and surgery. We performed correlation analysis of the two study instruments using the Pearson's correlation coefficient. Specific GSS subscales showed correlation with NEI-VFQ-25 subscales designed to capture similar constructs, but did not correlate with subscales describing different HRQoL domains. This suggests that the two questionnaires give complementary, but not overlapping, information on vision-related QoL of patients with POAG.
To the best of our knowledge, the current study represents the largest investigation on this subject. Many of the studies on QoL in glaucoma were conducted in significantly smaller samples. Moreover, as some of these were designed for the validation of instruments or their translated versions, rather than the characterization of vision-related QoL, limited attention was paid to the representativeness of the patient populations (Janz et al. 2001; Mangione et al. 2001; Rossi et al. 2003 Rossi et al. , 2013 Uenishi et al. 2003; Labiris et al. 2008 Labiris et al. , 2010 McKeanCowdin et al. 2008; Wang et al. 2008; Yamagishio et al. 2009; Lin & Yang 2010; Hirneiss et al. 2011; Sawada et al. 2011; Mbadugha et al. 2012; Onakoya et al. 2012; Wolfram et al. 2013; Zhou et al. 2013a,b) . The large sample size and wide geographical distribution suggest that study results may be representative for the Italian population of patients treated for POAG. However, we are unable to exclude a selection bias towards patients with less severe disease and better preserved HRQoL as information on individuals who refused participation was not collected. Our sample cannot be considered representative in a strict methodological sense, because the practical means of ensuring 'representativeness' (i.e. random inclusion from a central nationwide registry) are not available. However, this sample is as close as pragmatically possible to being representative by virtue of its wideranging geographical distribution, origin from diverse academic and nonacademic centres, and size. Furthermore, it is possible that not all included participants are necessarily patients with glaucoma. Just as is typical in most clinical centres, however, these 'suspects' are managed in a fashion similar to patients with glaucoma.
Another possible limitation of the present study is that it focuses on visual and daily function, rather than general health and psychological well-being aspects of QoL. This was mainly due to the unavailability of validated Italian versions of questionnaires assessing general health and psychological attributes of QoL. However, our common experience as members of the Italian Study Group on QoL in Glaucoma is that visual and functional symptoms are major determinants of a patient's subjective well-being. This notion is supported by the results of a recent study (Skalicky & Goldberg 2008) , which showed depression in patients with glaucoma was associated with increasing disease severity.
In summary, this study indicated that self-administered HRQoL instruments are acceptable to patients and provide detailed information on the clinical burden of glaucoma and its effects on visual loss, daily functioning and other dimensions of HRQoL. Overall, patient well-being can be preserved throughout the early and moderate stages of disease but will decline with progressive visual loss. These findings stress the importance of early diagnosis and timely and appropriate therapeutic approaches.
Further analyses are warranted to better characterize potential additional factors, which may interfere with HRQoL in patients with POAG and to evaluate vision-related functioning and well-being across different stages of the disease.
